Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study

被引：0
作者：
Zhi-Bin Ke
Shao-Ming Chen
Jia-Yin Chen
Shao-Hao Chen
Qi You
Jiang-Bo Sun
Yu-Ting Xue
Xiong-Lin Sun
Xiao-Hui Wu
Qing-Shui Zheng
Yong Wei
Xue-Yi Xue
Ning Xu
机构：
[1] Fujian Medical University,Department of Urology, Urology Research Institute, the First Affiliated Hospital
[2] Fujian Medical University,Department of Nuclear Medicine, the First Affiliated Hospital
[3] Fujian Medical University,Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Prostate cancer; [; Ga]Ga-PSMA-11 PET/CT; Pathological responses; Neoadjuvant chemohormonal therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1240 / 1251
页数：11
相关论文
共 178 条
[1]  
Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33
[2]  
Miller KD(2014)High-risk prostate cancer-classification and therapy Nat Rev Clin Oncol 11 308-323
[3]  
Fuchs HE(2019)Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study Urol Oncol 37 991-998
[4]  
Jemal A(2014)Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer J Hematol Oncol 7 20-436
[5]  
Chang AJ(2021)Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis Asian J Androl 23 429-3050
[6]  
Autio KA(2020)Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer J Clin Oncol 38 3042-953
[7]  
Roach M(2013)Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy J Buon 18 949-532
[8]  
Scher HI(2020)Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard J Nucl Med 61 527-1216
[9]  
Pan J(2020)Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet 395 1208-1160
[10]  
Chi C(2020)Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study J Nucl Med 61 1153-1593
12345678910